Introduction: Neoadjuvant chemotherapy (NAC) has the potential for tumor downstaging and surgery de-escalation. In the axilla, this approach is less established, especially in cN+→ycN0. Targeted axillary dissection is an option, but difficult to concretize. We aim to identify biological factors associated with nodal pathological complete response (pCR) and recognize potential candidates for a more conservative ...